Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects

32Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The pharmacokinetics of a single 400 mg oral dose of valnoctamide (VCD) has been investigated in seven healthy, adult, male volunteers. VCD was not biotransformed rapidly to its corresponding acid valnoctic acid (VCA), unlike its isomer valpromide (VPD). It had a mean residence time of 13.2 h and a terminal half-life of 9.3 h. Throughout the study, only low plasma levels of VCA could be detected. Thus, unlike VPD, which is a prodrug of the corresponding acid, (valproic acid, VPA). VCD appears to act as a drug in its own right, and it does not undergo similar hydrolysis. The pharmacokinetic difference may account for the different pharmacological activities of the two isomers. © 1990 Springer-Verlag.

Cite

CITATION STYLE

APA

Bialer, M., Haj-Yehia, A., Barzaghi, N., Pisani, F., & Perucca, E. (1990). Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. European Journal of Clinical Pharmacology, 38(3), 289–291. https://doi.org/10.1007/BF00315032

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free